Overview

  • Product name

    Anti-Met (c-Met) antibody [EPR22436-24]
    See all Met (c-Met) primary antibodies
  • Description

    Rabbit monoclonal [EPR22436-24] to Met (c-Met)
  • Host species

    Rabbit
  • Tested applications

    Suitable for: WB, ICC/IF, Flow Cyt, IPmore details
    Unsuitable for: IHC-P
  • Species reactivity

    Reacts with: Mouse
  • Immunogen

    Recombinant fragment within Human Met (c-Met) aa 1-550. The exact sequence is proprietary.
    Database link: P16056

  • Positive control

    • WB: B16-F10 and NIH/3T3 whole cell lysate. ICC/IF: B16-F10 cells. Flow: NIH/3T3 cells. IP: B16-F10 whole cell lysate.
  • General notes

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.

    This product is a recombinant rabbit monoclonal antibody.

Properties

Applications

Our Abpromise guarantee covers the use of ab216330 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/1000. Predicted molecular weight: 155 kDa.
ICC/IF 1/50.
Flow Cyt 1/500.
IP 1/30.
  • Application notes
    Is unsuitable for IHC-P.
  • Target

    • Function

      Receptor for hepatocyte growth factor and scatter factor. Has a tyrosine-protein kinase activity. Functions in cell proliferation, scattering, morphogenesis and survival.
    • Involvement in disease

      Note=Activation of MET after rearrangement with the TPR gene produces an oncogenic protein.
      Note=Defects in MET may be associated with gastric cancer.
      Defects in MET are a cause of hepatocellular carcinoma (HCC) [MIM:114550].
      Defects in MET are a cause of renal cell carcinoma papillary (RCCP) [MIM:605074]. It is a subtype of renal cell carcinoma tending to show a tubulo-papillary architecture formed by numerous, irregular, finger-like projections of connective tissue. Renal cell carcinoma is a heterogeneous group of sporadic or hereditary carcinoma derived from cells of the proximal renal tubular epithelium. It is subclassified into common renal cell carcinoma (clear cell, non-papillary carcinoma), papillary renal cell carcinoma, chromophobe renal cell carcinoma, collecting duct carcinoma with medullary carcinoma of the kidney, and unclassified renal cell carcinoma.
      Note=A common allele in the promoter region of the MET shows genetic association with susceptibility to autism in some families. Functional assays indicate a decrease in MET promoter activity and altered binding of specific transcription factor complexes.
      Note=MET activating mutations may be involved in the development of a highly malignant, metastatic syndrome known as cancer of unknown primary origin (CUP) or primary occult malignancy. Systemic neoplastic spread is generally a late event in cancer progression. However, in some instances, distant dissemination arises at a very early stage, so that metastases reach clinical relevance before primary lesions. Sometimes, the primary lesions cannot be identified in spite of the progresses in the diagnosis of malignancies.
    • Sequence similarities

      Belongs to the protein kinase superfamily. Tyr protein kinase family.
      Contains 3 IPT/TIG domains.
      Contains 1 protein kinase domain.
      Contains 1 Sema domain.
    • Domain

      The kinase domain is involved in SPSB1 binding.
    • Post-translational
      modifications

      Dephosphorylated by PTPRJ at Tyr-1349 and Tyr-1365.
    • Cellular localization

      Membrane.
    • Information by UniProt
    • Database links

    • Alternative names

      • AUTS9 antibody
      • c met antibody
      • D249 antibody
      • Hepatocyte growth factor receptor antibody
      • HGF antibody
      • HGF receptor antibody
      • HGF/SF receptor antibody
      • HGFR antibody
      • MET antibody
      • Met proto oncogene antibody
      • Met proto oncogene tyrosine kinase antibody
      • MET proto oncogene, receptor tyrosine kinase antibody
      • Met proto-oncogene (hepatocyte growth factor receptor) antibody
      • Met proto-oncogene antibody
      • Met protooncogene antibody
      • MET_HUMAN antibody
      • Oncogene MET antibody
      • Par4 antibody
      • Proto-oncogene c-Met antibody
      • RCCP2 antibody
      • Scatter factor receptor antibody
      • SF receptor antibody
      • Tyrosine-protein kinase Met antibody
      see all

    Images

    • All lanes : Anti-Met (c-Met) antibody [EPR22436-24] (ab216330) at 1/1000 dilution

      Lane 1 : B16-F10 (mouse melanoma mixture of spindle-shaped and epithelial-like cells) whole cell lysate
      Lane 2 : NIH/3T3 (mouse embryonic fibroblast) whole cell lysate

      Lysates/proteins at 20 µg per lane.

      Secondary
      All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/20000 dilution

      Predicted band size: 155 kDa
      Observed band size: 175 kDa
      why is the actual band size different from the predicted?



      Blocking/diluting buffer and concentration: 5% NFDM/TBST 

      Exposure time: 26 seconds.

      Negative control: NIH/3T3 (PMID: 21496277; PMID: 8197126; PMID 9888438)

      The molecular weight observed is consistent with what has been described in the literature (PMID: 8710887).

    • Met (c-Met) was immunoprecipitated from 0.35mg of B16-F10 (Mouse melanoma mixture of spindle-shaped and epithelial-like cells) whole cell lysate using ab216330 at 1/30 dilution. WB was performed on the immunoprecipitate using ab216330 at 1/1000 dilution, followed by the VeriBlot for IP Detection Reagent (HRP) (ab131366) at 1/1000 dilution.

      Lane 1: B16-F10 whole cell lysate 10µg (input).
      Lane 2: ab216330 IP in B16-F10 whole cell lysate.
      Lane 3: Rabbit monoclonal IgG (ab172730) instead of ab216330 in B16-F10 whole cell lysate.

      Blocking and dilution buffer and concentration: 5% NFDM/TBST.
      Exposure time: 30 seconds.

       

    • Flow cytometric analysis of 4% paraformaldehyde-fixed NIH/3T3 (Mouse embryonic fibroblast, Left) / B16-F10 (Mouse melanoma mixture of spindle-shaped and epithelial-like cells, Right) labeling Met (c-Met) with ab216330 at 1/500 dilution (red) compared with a Rabbit monoclonal IgG (ab172730, Black) isotype control and an unlabelled control (cells without incubation with primary antibody and secondary antibody, Blue). A Goat anti rabbit IgG (Alexa Fluor® 488, ab150077) was used as the secondary antibody at 1/2000 dilution.

      Negative control: NIH/3T3(PMID: 21496277, 8197126, 9888438).

      Gated on viable cells.

    • Immunofluorescent analysis of 4% paraformaldehyde-fixed, 0.1% Triton X-100 permeabilized B16-F10 (mouse melanoma mixture of spindle-shaped and epithelial-like cells) and NIH/3T3 (mouse embryonic fibroblast) cells labelling Met (c-Met) with ab216330 with ab216330 at 1/50 dilution, followed by a AlexaFluor®488 Goat anti-Rabbit secondary (ab150077) at 1/1000 dilution (green). Confocal image showing membranous and cytoplasmic staining in B16-F10 cell line.  Tubulin was counterstained using an Anti-alpha Tubulin antibody [DM1A] - Microtubule Marker (Alexa Fluor® 594) at 1/200 dilution. The nuclear counterstain was DAPI (Blue).

      Negative control: NIH/3T3 (PMID: 21496277, 8197126, 9888438)

    References

    ab216330 has not yet been referenced specifically in any publications.

    Customer reviews and Q&As

    There are currently no Customer reviews or Questions for ab216330.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
    For licensing inquiries, please contact partnerships@abcam.com

    Sign up